

Liver Support

Isula A4+, our journey continues - testing and studies.

In the previous two newsletters, we at **Sabell Corporation** filled you in on our relationship with Dr. Cabanillas and how we decided to get behind **Isula A4+**, by sharing the story of a persistent mother fighting for the life of her son, Jarad. Let us now take you a step further on our journey.

With Jarad's remarkable improvement in the fall of 2000, we undertook a small four-week test with six volunteers who had chronic hepatitis of various degrees of severity. No adverse side effects were reported, and even though there were no significant changes to viral loads or to baseline liver enzyme levels, all patients experienced profound clinical improvement. Although this study was short in duration, the results were very promising and encouraged a more thorough investigation into **Isula A4+**.

A controlled clinical test was then undertaken between May and June in 2004. This 30-day test would assess the clinical, hematological, biochemical, ultrasound, and anatomic manifestations in a group of ten voluntary patients who carried chronic Hepatitis C. Five of the patients were men and five were women, all of whom had been living with the virus between four to thirty years.

By day 28 of the study, the patients had improved in every aspect of Hepatitis C symptomology. This was demonstrated by the biochemical liver testing (in relation to hepatic synthesis) and liver inflammation (shown in ultrasound testing).

These tests, in combination with the marked improvement demonstrated by results on the "Quality of Life SF-36" scale and the Beck Depression Inventory, provided evidence of marked decrease of liver inflammation, near elimination of Hepatitis C symptoms, and an overall sense of hope for leading a healthy, normal life. The authors concluded that with the significant physical and mental indicators of marked improvement in such a high percentage of the patients, continued research of **Isula A4+** was clearly warranted.

The authors stated no patient reported unpleasant side effects from the therapy performed on them; however, hematological and renal function control tests must be performed periodically. **Isula A4+** constitutes a very optimistic alternative treatment for patients with chronic Hepatitis C.

Subsequently, **Sabell Corporation** decided to go "all in" and attempt to develop and distribute **Isula A4+** to the millions of individuals who could benefit. However, in order to gain the necessary approvals and the product license that was eventually received in July of 2012, more had to be done.

In order to prove safety, toxicology testing was performed. In order to understand how and why **Isula A4+** was effective, anti-viral research was conducted along with research to evaluate the anti-oxidant, anti-inflammatory, and mucosal protective actions of **Isula A4+**.

Much was uncovered and explained including a much needed understanding as to why **Isula A4+** was so helpful in reducing the crippling nausea experienced by so many individuals inflicted with chronic hepatitis.

Sabell Corporation during this time was also able to convert **Isula A4+** from a hydro-alcoholic extract into the powder available today through our good friends at **Ecotrend**.

If you would like more information on the studies mentioned do not hesitate to contact your **Ecotrend** sales representative.

Isula A4+ constitutes a very optimistic alternative treatment for patients with chronic Hepatitis C.

